NPS Appoints Francois Nader, M.D., to Executive Vice President and COO

October 24th, 2008 by medicationguide

PARSIPPANY, N.J., July 3 /PRNewswire-FirstCall/ — NPS Pharmaceuticals,
Inc. (Nasdaq: NPSP) announced today the promotion of Francois Nader, M.D., to
executive vice president and chief operating officer.Dr. Nader joined NPS in
June 2006 as chief medical and commercial officer.Prior to joining NPS, he
was a venture partner at Care Capital, LLC, a life-science venture capital
firm.Previously, he served as senior vice president, Integrated Healthcare
Markets and head, North American Medical and Regulatory Affairs at Aventis
Pharmaceuticals.His pharmaceutical career began at Rhone-Poulenc, where he
held several positions of increasing responsibility, including Head of Global
Commercial Operations in the Pasteur Vaccines division.

In his new role, Dr. Nader will be responsible for managing NPS’s research
and development, regulatory affairs and commercial operations along with
planning and implementing the company’s outsourcing business model, announced
as part of the recent restructuring of operations.He will continue to report
to NPS president and CEO, Tony Coles, M.D.

Dr. Coles stated:”This appointment reflects the valuable strategic and
operations management skills which Francois brings to NPS and their importance
to our company as we execute our aggressive restructuring plan and focus our
investments on our late-stage assets.We have great confidence in Francois’
abilities and leadership to advance our product pipeline and we look forward
to his continuing contributions to NPS’s success.”

About NPS Pharmaceuticals

NPS discovers and develops small molecules and recombinant proteins as
drugs, primarily for the treatment of metabolic, bone and mineral, and central
nervous system disorders.The company has drug candidates in various stages
of clinical development backed by a strong discovery research effort.
Additional information is available on the company’s website,

Safe Harbor Statement

Note: Statements made in this press release, which are not historical in
nature, constitute forward-looking statements for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995. These
statements are based on management’s current expectations and beliefs and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. All information in this press release is as of July 3, 2007 and we
undertake no duty to update this information. A more complete description of
these risks can be found in our filings with the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the year-ended
December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-ended
March 31, 2007.

Hello world!

October 23rd, 2008 by medicationguide

Welcome to This is your first post. Edit or delete it, then start blogging!